These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22594682)

  • 1. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
    Lyles SE; Milner RJ; Kow K; Salute ME
    Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
    Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
    Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effects of Yunnan Baiyao on canine hemangiosarcoma cell lines.
    Wirth KA; Kow K; Salute ME; Bacon NJ; Milner RJ
    Vet Comp Oncol; 2016 Sep; 14(3):281-94. PubMed ID: 24976212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
    Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line.
    Thamm DH; Dickerson EB; Akhtar N; Lewis R; Auerbach R; Helfand SC; MacEwen EG
    Res Vet Sci; 2006 Aug; 81(1):76-86. PubMed ID: 16256156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma.
    Marley K; Maier CS; Helfand SC
    Vet Comp Oncol; 2012 Sep; 10(3):214-22. PubMed ID: 22487216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.
    Lawrence J; Saba C; Gogal R; Lamberth O; Vandenplas ML; Hurley DJ; Dubreuil P; Hermine O; Dobbin K; Turek M
    Vet Comp Oncol; 2012 Jun; 10(2):143-54. PubMed ID: 22236016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
    Turek M; Gogal R; Saba C; Vandenplas ML; Hill J; Feldhausser B; Lawrence J
    Res Vet Sci; 2014 Apr; 96(2):304-7. PubMed ID: 24602916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
    Pyuen AA; Meuten T; Rose BJ; Thamm DH
    PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro effects of doxorubicin and tetrathiomolybdate on canine hemangiosarcoma cells.
    Sloan CQ; Rodriguez CO
    Am J Vet Res; 2018 Feb; 79(2):219-225. PubMed ID: 29359968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
    Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
    Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.
    Mencalha AL; Du Rocher B; Salles D; Binato R; Abdelhay E
    Cancer Chemother Pharmacol; 2010 May; 65(6):1039-46. PubMed ID: 19701750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
    Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
    Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
    Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effects of the chemotherapy agent water-soluble micellar paclitaxel (Paccal Vet) on canine hemangiosarcoma cell lines.
    Reckelhoff CR; Lejeune A; Thompson PM; Shiomitsu K
    Vet Comp Oncol; 2019 Mar; 17(1):32-41. PubMed ID: 30267450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
    U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
    J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
    Wolfesberger B; Tonar Z; Gerner W; Skalicky M; Heiduschka G; Egerbacher M; Thalhammer JG; Walter I
    Res Vet Sci; 2010 Feb; 88(1):94-100. PubMed ID: 19665156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines.
    Witter LE; Gruber EJ; Lean FZ; Stokol T
    Am J Vet Res; 2017 Jan; 78(1):69-79. PubMed ID: 28029283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
    Grant J; North S; Lanore D
    J Small Anim Pract; 2016 Jun; 57(6):283-90. PubMed ID: 27136424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.